StockMarketWire.com - ReNeuron Group said dosing of a second cohort of subjects had commenced as part of a clinical trial of a treatment for the blindness-causing disease, retinitis pigmentosa.

The new dosing stage of the Phase I/II clinical trial followed a positive Data Safety Monitoring Board review of the clinical data from the first patient cohort in the study.

The first subject in the second cohort was treated last week at Massachusetts Eye and Ear, in Boston.

'This next dose cohort comprises patients who have a greater baseline level of visual acuity than those treated in the study thus far, thus providing a framework to better evaluate the safety of the treatment and to gain further clarity on the strong efficacy signal that was seen in the first Phase II cohort,' the company said.

As previously reported, the company said it expected to report further short term read-outs in mid-2019 from the ongoing study.


At 8:26am: [LON:RENE] ReNeuron Group PLC share price was +2.5p at 72.5p



Story provided by StockMarketWire.com